CAR T-Cell Vector With Inducible HP-NAP for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T-cell immunotherapy is limited in effectiveness for solid tumors due to the complex structure and immunosuppressive microenvironment of these tumors, which hinder the efficacy of CAR T-cells in reaching and targeting malignant cells.
Innovation Solution
Genetically modified T-cells expressing a chimeric antigen receptor (CAR) and Helicobacter pylori neutrophil activating protein (HP-NAP) or its immunological equivalent, with an inducible promoter for HP-NAP expression, enhance cytotoxicity and stimulate chemokine and cytokine secretion, promoting dendritic cell maturation and Th1 polarization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T-cells are used to treat solid tumors, then tumor targeting capability is improved, but effectiveness is limited due to immunosuppressive microenvironment
Solution Approach 1:
The patent introduces HP-NAP as an intermediary protein expressed by CAR T-cells to modulate the tumor microenvironment. HP-NAP acts as a mediator that recruits innate immune cells and matures dendritic cells, thereby transforming the immunosuppressive microenvironment into a more favorable setting for tumor elimination, thus resolving the contradiction between targeting capability and therapy effectiveness
Solution Approach 2:
The patent changes the functional parameters of CAR T-cells by inducing them to express HP-NAP, which alters the chemical and biological parameters of the tumor microenvironment. This parameter change enables CAR T-cells to overcome immunosuppression and enhance their effectiveness in treating solid tumors while maintaining their targeting capability
2Strength
If CAR T-cells are engineered with HP-NAP expression, then cytotoxicity is improved, but device complexity increases
Solution Approach 1:
The patent merges the CAR expression cassette with the HP-NAP expression cassette into a single genetic modification system. By combining these functions into one integrated approach using the same vector and promoter system, the patent enhances cytotoxicity while minimizing the increase in genetic modification complexity
Solution Approach 2:
The patent creates multi-functional CAR T-cells that simultaneously express CAR for tumor targeting and HP-NAP for immunomodulation. This universal approach allows a single cell line to perform multiple functions (targeting, cytotoxicity, and microenvironment modulation) without requiring separate genetic modifications, thus improving strength while controlling complexity
3Adaptability or versatility
If HP-NAP is expressed constitutively, then immunomodulatory capability is improved, but harmful effects increase due to systemic activation
Solution Approach 1:
The patent transitions from static constitutive HP-NAP expression to dynamic inducible expression controlled by the NFAT-IL-2 promoter. The promoter is activated only upon T-cell engagement with tumor antigens, ensuring HP-NAP is expressed dynamically in response to tumor presence rather than constitutively, thus improving adaptability while reducing harmful systemic effects
Solution Approach 2:
The patent implements a feedback mechanism where T-cell activation by tumor antigens triggers NFAT-IL-2 promoter activation, which in turn induces HP-NAP expression. This feedback loop ensures HP-NAP is produced only when and where tumor antigens are present, enhancing immunomodulatory capability at the tumor site while preventing harmful systemic activation
Data Source
AI summary
A virus vector comprises a constitutive promoter, a nucleic acid sequence encoding a chimeric antigen receptor (CAR), an inducible promoter comprising N nuclear factor of activated T-cells (NFAT) binding motifs followed by the minimal human interleukin 2 (IL-2) promoter, and a nucleic acid sequence encoding a Helicobacter pylori neutrophil activating protein (HP-NAP) and/or an immunological equivalent fragment thereof. The virus vector may be provided in a T-cell useful in T-cell immunotherapy. The T-cells have improved effects in immunotherapy including treating, reducing and/or preventing cancer in a patient.